SEC Form 4 · accession 0001012975-17-000478
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sybil Tasker
Officer — Chief Medical Officer
Period of report
Jun 6, 2017
Accepted (ET)
Jun 8, 2017 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $4.12 | Jun 6, 2017 | A | 40,000 | A | — | Jun 6, 2027 | Common Stock, par value $0.0001 | 40,000 | 40,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable in four equal annual installments commencing on the first anniversary of the date of grant.